PYXS
Pyxis Oncology, Inc.
$3.08
-1.28%
2026-08-21
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Key Fundamentals
Forward P/E
-2.51
EPS (TTM)
$-1.40
ROE
-179.1%
Profit Margin
0.0%
Debt/Equity
155.87
Price/Book
6.04
Beta
1.31
Market Cap
$190.7M
Avg Volume (10D)
2.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$4.00
60D Low
$1.54
Avg Volume
1.2M
Latest Close
$3.08
Get breakout alerts for PYXS
Sign up for Breakout Scanner to receive daily notifications when PYXS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Pyxis Oncology, Inc. (PYXS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PYXS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PYXS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.